A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer’s disease. Recently published in Neurobiology of Aging, the study demonstrates that the drug improves memory deficits and reverses brain cell damage, offering hope for improving cognitive functioning, delaying Alzheimer’s progression, and potentially preventing some of the brain damages associated with the disease.
Alzheimer’s disease is the most common form of dementia, and nearly 50 million people worldwide are affected by Alzheimer’s or related dementia. It is a progressive neurological condition that leads to memory loss, cognitive decline, and changes in behaviours, significantly impacting…